Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15688572 | 0.67 | LMNA (0.39) | — | |
| SCHEMBL10753654 | 0.63 | HSP90AB1 (0.37) | — | |
| SCHEMBL31387681 | 0.63 | HSP90AB1 (0.37) | — | |
| SCHEMBL3118903 | 0.63 | ALDH1A1 (0.35) | — | |
| SCHEMBL16122136 | 0.63 | LMNA (0.39) | — | |
| SCHEMBL12986501 | 0.60 | ALDH1A1 (0.36) | — | |
| SCHEMBL11443724 | 0.60 | — | — | |
| SCHEMBL17239888 | 0.60 | LMNA (0.38) | — | |
| SCHEMBL9413896 | 0.58 | ABCB1 (0.53) | — | |
| SCHEMBL4981379 | 0.58 | HSP90AB1 (0.46) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604989-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9604989-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9604989-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| CN-103596957-B | Imidazopyridazines as AKT kinase inhibitors | 拜耳知识产权有限责任公司 | 2016-12-07 | — | — | CN | disclosed |
| US-20150368250-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| US-20150368250-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| US-20150368250-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| US-9206185-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206185-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206185-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| EP-2694510-B1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER IP GMBH (DE) | 2015-10-14 | — | — | EP | disclosed |
| EP-2694510-B1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER IP GMBH (DE) | 2015-10-14 | — | — | EP | disclosed |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2694510-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012136776-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136776-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368250-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | PI4KA, PI4KB, PIK3CD | NUDT1 1880/4885 |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | PI4KA, PI4KB, PIK3CD | NUDT1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.